Founded in March 2017, IASO BIO is a clinical stage biotechnology company advancing the development of innovative cell therapies for cancer. The company is dedicated to curing cancer using autologous/allogenic T cell therapies to enhance the immune system's ability to recognize and eradicate cancer cells. IASO BIO is developing over 10 high-potential, high-end biopharmaceutical products, targeting hematological and solid tumors. Additional development efforts include unique TCR-like CAR-T cell therapy products for indications such as gastric cancer, nasopharyngeal carcinoma and viral infection related solid tumors.
